Clinical Evaluation of Drug–Drug Interactions With Aficamten
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2026-03-01
|
| Seri Bilgileri: | Clinical and Translational Science |
| Konular: | |
| Online Erişim: | https://doi.org/10.1111/cts.70514 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|